Absci Corporation (Nasdaq: ABSI) has started an underwritten public offering of $50 million of its common stock, with a 30-day option for underwriters to purchase an additional $7.5 million. The proceeds will fund internal programs, the Integrated Drug Creation™ platform, and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities (USA) LLC are joint book-running managers. The offering is subject to market conditions. Absci’s generative AI drug creation aims to create better biologics for patients. Forward-looking statements regarding the offering are subject to risks and uncertainties, as outlined in their SEC filings.

Read more at GlobeNewswire: Absci Announces Proposed Public Offering of Common Stock